Analyst Price Targets — INSM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 10:15 am | — | Wells Fargo | $161.00 | $110.11 | TheFly | Insmed price target raised to $161 from $160 at Wells Fargo |
| June 16, 2026 10:40 am | Graig Suvannavejh | Mizuho Securities | $192.00 | $97.46 | StreetInsider | Insmed (INSM) PT Lowered to $192 at Mizuho |
| May 13, 2026 5:11 pm | — | Truist Financial | $185.00 | $116.56 | TheFly | Insmed price target lowered to $185 from $205 at Truist |
| May 8, 2026 11:49 am | — | Wells Fargo | $160.00 | $105.00 | TheFly | Insmed price target lowered to $160 from $177 at Wells Fargo |
| May 8, 2026 11:11 am | Vamil Divan | Guggenheim | $226.00 | $105.00 | TheFly | Insmed price target lowered to $226 from $230 at Guggenheim |
| April 16, 2026 10:48 am | — | Guggenheim | $230.00 | $146.74 | TheFly | Insmed price target raised to $230 from $227 at Guggenheim |
| April 14, 2026 11:08 am | — | RBC Capital | $216.00 | $151.14 | TheFly | Insmed price target raised to $216 from $212 at RBC Capital |
| April 10, 2026 9:32 am | — | Raymond James | $200.00 | $155.80 | TheFly | Insmed initiated with an Outperform at Raymond James |
| April 8, 2026 12:38 pm | — | Mizuho Securities | $202.00 | $160.18 | TheFly | Insmed price target lowered to $202 from $206 at Mizuho |
| March 26, 2026 3:13 pm | — | H.C. Wainwright | $245.00 | $147.60 | TheFly | Insmed price target raised to $245 from $230 at H.C. Wainwright |
Latest News for INSM
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) patients.
Insmed NASDAQ: INSM reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures and a generally favorable safety profile over longer-term use.
– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12– –TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once…
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INSM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.